135 related articles for article (PubMed ID: 10582905)
1. Comparative bacteriostatic and bactericidal activities of cefodizime against Borrelia burgdorferi sensu lato.
Murgia R; Marchetti F; Cinco M
Antimicrob Agents Chemother; 1999 Dec; 43(12):3030-2. PubMed ID: 10582905
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics.
Baradaran-Dilmaghani R; Stanek G
Infection; 1996; 24(1):60-3. PubMed ID: 8852472
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone.
Agger WA; Callister SM; Jobe DA
Antimicrob Agents Chemother; 1992 Aug; 36(8):1788-90. PubMed ID: 1416868
[TBL] [Abstract][Full Text] [Related]
4. Comparative activity of cefodizime and ceftriaxone against respiratory pathogens in an in vitro pharmacodynamic model simulating concentration-time curves.
Blandino G; Milazzo I; Musumeci R; Nicolosi VM; Speciale A; Nicoletti G
J Chemother; 2000 Dec; 12(6):503-8. PubMed ID: 11154034
[TBL] [Abstract][Full Text] [Related]
5. Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis.
Preac Mursic V; Marget W; Busch U; Pleterski Rigler D; Hagl S
Infection; 1996; 24(1):9-16. PubMed ID: 8852456
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of Borrelia burgdorferi strains isolated in the Czech Republic.
Janovská D; Hulínská D; Godová T
Cent Eur J Public Health; 2001 Feb; 9(1):38-40. PubMed ID: 11243589
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto.
Sicklinger M; Wienecke R; Neubert U
J Clin Microbiol; 2003 Apr; 41(4):1791-3. PubMed ID: 12682190
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.
Kraiczy P; Weigand J; Wichelhaus TA; Heisig P; Backes H; Schäfer V; Acker G; Brade V; Hunfeld KP
Antimicrob Agents Chemother; 2001 Sep; 45(9):2486-94. PubMed ID: 11502519
[TBL] [Abstract][Full Text] [Related]
9. Lyme disease: disparity between culture and polymerase chain reaction detection of Borrelia burgdorferi after exposure to ceftriaxone in vitro.
Varde S; Wormser GP; Nowakowski J; Nadelman RB; Bittker S; Cooper D; Schwartz I
Conn Med; 1999 Oct; 63(10):589-91. PubMed ID: 10578549
[TBL] [Abstract][Full Text] [Related]
10. Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates.
Hunfeld KP; Kraiczy P; Wichelhaus TA; Schäfer V; Brade V
Int J Antimicrob Agents; 2000 Jun; 15(1):11-7. PubMed ID: 10856671
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease.
Pavia CS; Wormser GP; Nowakowski J; Cacciapuoti A
Antimicrob Agents Chemother; 2001 Mar; 45(3):936-7. PubMed ID: 11181384
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of cefodizime and other antibiotics against pathogens recently isolated in Italy.
Nicoletti G; Blandino G; Cocuzza G; Dainelli B; Maida A; Debbia E; Schito G
Chemotherapy; 1996; 42(2):100-6. PubMed ID: 8697884
[TBL] [Abstract][Full Text] [Related]
13. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites.
Kazragis RJ; Dever LL; Jorgensen JH; Barbour AG
Antimicrob Agents Chemother; 1996 Nov; 40(11):2632-6. PubMed ID: 8913478
[TBL] [Abstract][Full Text] [Related]
14. Cefodizime: effects of sub-inhibitory concentrations on adhesiveness and bacterial morphology of Staphylococcus aureus and Escherichia coli: comparison with cefotaxime and ceftriaxone.
Braga PC; Dal Sasso M; Maci S
J Antimicrob Chemother; 1997 Jan; 39(1):79-84. PubMed ID: 9044031
[TBL] [Abstract][Full Text] [Related]
15. Antibiotics and increased temperature against Borrelia burgdorferi in vitro.
Reisinger E; Wendelin I; Gasser R; Halwachs G; Wilders-Truschnig M; Krejs G
Scand J Infect Dis; 1996; 28(2):155-7. PubMed ID: 8792482
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of faropenem, ertapenem, imipenem and meropenem against Borrelia burgdorferi s.l.
Rödel R; Freyer A; Bittner T; Schäfer V; Hunfeld KP
Int J Antimicrob Agents; 2007 Jul; 30(1):83-6. PubMed ID: 17512703
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of Borrelia burgdorferi isolates to three antibiotics commonly used for treating equine Lyme disease.
Caol S; Divers T; Crisman M; Chang YF
BMC Vet Res; 2017 Sep; 13(1):293. PubMed ID: 28962614
[TBL] [Abstract][Full Text] [Related]
18. New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances.
Hunfeld KP; Kraiczy P; Wichelhaus TA; Schäfer V; Brade V
Eur J Clin Microbiol Infect Dis; 2000 Jan; 19(1):27-32. PubMed ID: 10706176
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of cefodizime, cefuroxime, ceftriaxone against respiratory pathogens.
Paniara O; Platsouka E; Dimopoulou H; Constantoulaki S
J Chemother; 1994 Feb; 6(1):35-8. PubMed ID: 8071676
[TBL] [Abstract][Full Text] [Related]
20. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.
Dever LL; Jorgensen JH; Barbour AG
J Clin Microbiol; 1992 Oct; 30(10):2692-7. PubMed ID: 1400969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
